PDF herunterladen
Onkologie up2date 2021; 3(03): 189-195
DOI: 10.1055/a-1510-5115
SOP / Arbeitsablauf

SOP Transarterielle Chemoembolisation zur Tumortherapie

Harald Ittrich
,
Henning Wege
,
Jörg Schrader
› Weitere Informationen
    Lizenzen und Reprints Alle Artikel dieser Rubrik

Die transarterielle Chemoembolisation (TACE) ist ein durchleuchtungsgesteuertes minimalinvasives transarterielles Verfahren zur Behandlung von primären (hepatozelluläres Karzinom, intrahepatisches Cholangiokarzinom) und sekundären Lebertumoren (Lebermetastasen). Sie kombiniert die Wirkung von Chemotherapeutika auf Tumoren bei gleichzeitiger Embolisation von tumorversorgenden arteriellen Gefäßen.

Schlüsselwörter

transarterielle Chemoembolisation - Indikationen - hepatozelluläres Karzinom - intrahepatisches Cholangiokarzinom - Lebermetastasen


Publikationsverlauf

Artikel online veröffentlicht:
03. September 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Bray F, Ferlay J, Soerjomataram I. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394-424 DOI: 10.3322/caac.21492.
    CrossrefPubMedGoogle Scholar
  • 2 Cummins ER, Vick KD, Poole GV. Incurable colorectal carcinoma: the role of surgical palliation. Am Surg 2004; 70: 433-437
    CrossrefPubMedGoogle Scholar
  • 3 Garrean S, Hering J, Saied A. et al. Radiofrequency ablation of primary and metastatic liver tumors: a critical review of the literature. Am J Surg 2008; 195: 508-520 DOI: 10.1016/j.amjsurg.2007.06.024.
    CrossrefPubMedGoogle Scholar
  • 4 Llovet JM, Fuster J, Bruix J. et al. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 2004; 10: S115-S120 DOI: 10.1002/lt.20034.
    CrossrefPubMedGoogle Scholar
  • 5 Johnson PJ, Berhane S, Kagebayashi C. et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach – the ALBI grade. J Clin Oncol 2015; 33: 550-558 DOI: 10.1200/JCO.2014.57.9151.
    CrossrefPubMedGoogle Scholar
  • 6 Lim L, Gibbs P, Yip D. et al. Prospective study of treatment with selective internal radiation therapy spheres in patients with unresectable primary or secondary hepatic malignancies. Intern Med J 2005; 35: 222-227 DOI: 10.1111/j.1445-5994.2005.00789.x.
    CrossrefPubMedGoogle Scholar
  • 7 Ensminger WD. Intrahepatic arterial infusion of chemotherapy: pharmacologic principles. Semin Oncol 2002; 29: 119-125 DOI: 10.1053/sonc.2002.31679.
    CrossrefPubMedGoogle Scholar
  • 8 Kerr DJ, Los G. Pharmacokinetic principles of locoregional chemotherapy. Cancer Surv 1993; 17: 105-122
    PubMedGoogle Scholar
  • 9 Liapi E, Geschwind JF. Transcatheter and ablative therapeutic approaches for solid malignancies. J Clin Oncol 2007; 25: 978-986 DOI: 10.1200/JCO.2006.09.8657.
    CrossrefPubMedGoogle Scholar
  • 10 Konno T, Maeda H, Yokoyama I. et al. [Use of a lipid lymphographic agent, lipiodol, as a carrier of high molecular weight antitumor agent, smancs, for hepatocellular carcinoma]. Gan To Kagaku Ryoho 1982; 9: 2005-2015
    PubMedGoogle Scholar
  • 11 Lammer J, Malagari K, Vogl T. et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33: 41-52 DOI: 10.1007/s00270-009-9711-7.
    CrossrefPubMedGoogle Scholar
  • 12 Vogl TJ, Zangos S, Eichler K. et al. Colorectal liver metastases: regional chemotherapy via transarterial chemoembolization (TACE) and hepatic chemoperfusion: an update. Eur Radiol 2007; 17: 1025-1034 DOI: 10.1007/s00330-006-0372-5.
    CrossrefPubMedGoogle Scholar
  • 13 Raoul JL, Heresbach D, Bretagne JF. et al. Chemoembolization of hepatocellular carcinomas. A study of the biodistribution and pharmacokinetics of doxorubicin. Cancer 1992; 70: 585-590
    CrossrefPubMedGoogle Scholar
  • 14 Sakamoto I, Aso N, Nagaoki K. et al. Complications associated with transcatheter arterial embolization for hepatic tumors. Radiographics 1998; 18: 605-619 DOI: 10.1148/radiographics.18.3.9599386.
    CrossrefPubMedGoogle Scholar
  • 15 Dufour JF, Bargellini I, De Maria N. et al. Intermediate hepatocellular carcinoma: current treatments and future perspectives. Ann Oncol 2013; 24 (Suppl. 02) ii24-ii29 DOI: 10.1093/annonc/mdt054.
    CrossrefPubMedGoogle Scholar
  • 16 Takayasu K, Arii S, Ikai I. et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006; 131: 461-469 DOI: 10.1053/j.gastro.2006.05.021.
    CrossrefPubMedGoogle Scholar
  • 17 Lencioni R, de Baere T, Soulen MC. et al. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data. Hepatology 2016; 64: 106-116 DOI: 10.1002/hep.28453.
    CrossrefPubMedGoogle Scholar
  • 18 Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003; 37: 429-442 DOI: 10.1053/jhep.2003.50047.
    CrossrefPubMedGoogle Scholar
  • 19 Chung GE, Lee JH, Kim HY. et al. Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. Radiology 2011; 258: 627-634 DOI: 10.1148/radiol.10101058.
    CrossrefPubMedGoogle Scholar
  • 20 Georgiades CS, Hong K, DʼAngelo M. et al. Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 2005; 16: 1653-1659 DOI: 10.1097/01.RVI.0000182185.47500.7A.
    CrossrefPubMedGoogle Scholar
  • 21 Varela M, Real MI, Burrel M. et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007; 46: 474-481 DOI: 10.1016/j.jhep.2006.10.020.
    CrossrefPubMedGoogle Scholar
  • 22 Facciorusso A, Di Maso M, Muscatiello N. Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: A meta-analysis. Dig Liver Dis 2016; 48: 571-577 DOI: 10.1016/j.dld.2016.02.005.
    CrossrefPubMedGoogle Scholar
  • 23 Kim JH, Yoon HK, Sung KB. et al. Transcatheter arterial chemoembolization or chemoinfusion for unresectable intrahepatic cholangiocarcinoma: clinical efficacy and factors influencing outcomes. Cancer 2008; 113: 1614-1622 DOI: 10.1002/cncr.23787.
    CrossrefPubMedGoogle Scholar
  • 24 Vogl TJ, Naguib NN, Nour-Eldin NE. et al. Transarterial chemoembolization in the treatment of patients with unresectable cholangiocarcinoma: Results and prognostic factors governing treatment success. Int J Cancer 2012; 131: 733-740 DOI: 10.1002/ijc.26407.
    CrossrefPubMedGoogle Scholar
  • 25 Kuhlmann JB, Euringer W, Spangenberg HC. et al. Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy. Eur J Gastroenterol Hepatol 2012; 24: 437-443 DOI: 10.1097/MEG.0b013e3283502241.
    CrossrefPubMedGoogle Scholar
  • 26 Ray jr CE, Edwards A, Smith MT. et al. Metaanalysis of survival, complications, and imaging response following chemotherapy-based transarterial therapy in patients with unresectable intrahepatic cholangiocarcinoma. J Vasc Interv Radiol 2013; 24: 1218-1226 DOI: 10.1016/j.jvir.2013.03.019.
    CrossrefPubMedGoogle Scholar
  • 27 Fiorentini G, Aliberti C, Tilli M. et al. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res 2012; 32: 1387-1395
    Google Scholar
  • 28 Stutz M, Mamo A, Valenti D. et al. Real-life report on chemoembolization using DEBIRI for liver metastases from colorectal cancer. Gastroenterol Res Pract 2015; 2015: 715102 DOI: 10.1155/2015/715102.
    CrossrefPubMedGoogle Scholar
  • 29 Kress O, Wagner HJ, Wied M. et al. Transarterial chemoembolization of advanced liver metastases of neuroendocrine tumors – a retrospective single-center analysis. Digestion 2003; 68: 94-101 DOI: 10.1159/000074522.
    CrossrefPubMedGoogle Scholar
  • 30 Loewe C, Schindl M, Cejna M. et al. Permanent transarterial embolization of neuroendocrine metastases of the liver using cyanoacrylate and lipiodol: assessment of mid- and long-term results. AJR Am J Roentgenol 2003; 180: 1379-1384 DOI: 10.2214/ajr.180.5.1801379.
    CrossrefPubMedGoogle Scholar
  • 31 Pitt SC, Knuth J, Keily JM. et al. Hepatic neuroendocrine metastases: chemo- or bland embolization?. J Gastrointest Surg 2008; 12: 1951-1960 DOI: 10.1007/s11605-008-0640-6.
    CrossrefPubMedGoogle Scholar
  • 32 Gupta S, Johnson MM, Murthy R. et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 2005; 104: 1590-1602 DOI: 10.1002/cncr.21389.
    CrossrefPubMedGoogle Scholar
  • 33 Eichler K, Jakobi S, Gruber-Rouh T. et al. Transarterial chemoembolisation (TACE) with gemcitabine: phase II study in patients with liver metastases of breast cancer. Eur J Radiol 2013; 82: e816-e822 DOI: 10.1016/j.ejrad.2013.08.046.
    CrossrefPubMedGoogle Scholar
  • 34 Cho SW, Kitisin K, Buck D. et al. Transcatheter arterial chemoembolization is a feasible palliative locoregional therapy for breast cancer liver metastases. Int J Surg Oncol 2010; 2010: 251621 DOI: 10.1155/2010/251621.
    CrossrefPubMedGoogle Scholar
  • 35 Khoja L, Atenafu EG, Suciu S. et al. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study. Ann Oncol 2019; 30: 1370-1380 DOI: 10.1093/annonc/mdz176.
    CrossrefPubMedGoogle Scholar